ESR1 and breast carcinoma: Consequently, models based on gene expression analysis have shown potential in correctly identifying patients with N0 status in specific subtypes of breast cancer, such as luminal A [47], ER+/HER2− [48], and triple-negative tumors [49], to capture additional aspects of lymphatic spread, such as immune signatures.